Researchers add to previous studies by refuting association between vaccines and MS flare-ups.
In a recent study published in JAMA Neurology, no link was found between receiving vaccinations and incidences of multiple sclerosis (MS) flare-ups.
MS is a disease resulting from abnormal immune system behavior, and it is currently the most prevalent demyelinating inflammatory disease impacting the central nervous system (CNS). Today, the cause of MS is still unknown. Given its relationship with the immune system, researchers have taken a particular interest in the role that infection or immunization play in MS and MS flare-up incidence.
Exposure to infections is known to increase the likelihood of flare-ups. For this reason, vaccination is primarily recommended as a strategy to prevent flare-up incidences in patients enduring MS. However, the authors reference a study by Langer-Gould et al that observed a possible connection between the onset of MS and vaccines. Although inconclusive, these findings have contributed to controversy and hesitancy over the years towards vaccination in cases of MS.
Grimaldi et al saw a need to conduct a large-scale study that further explored the correlation between vaccines and incidence of severe MS flare-ups. They gathered data from System of National Health Databases (SNDS) between January 1, 2007 and December 31, 2017 on patients who met the criteria for long-term MS (MS-ALD code).
The MS cohort consisted of 106,523 patients in France. Patient flare-ups were flagged if they resulted in hospitalization of at least 1 day and an overnight stay specifically linked to MS. Flare-ups were also assessed in accordance with an "at-risk" period classified as the 60 days before and including a patient’s hospitalization date. Patients were only included if they were followed up with for at least 12 months and did not go more that 24 months without follow-up.
Vaccines listed in the authors’ analysis are as follows:
Patients engaged in follow-up for an average of 8.8 years after their entry into the cohort. Of the 106,523 individuals, 35,265 (33.1%) experienced MS flare-ups at least once that required hospitalization. In total, their flare-ups resulted in 54,036 hospitalizations.
Hospitalization rates were measured in events per 100 person-years. Results showed rates of 5.78 incidences per 100 person-years, which was reduced to 3.85 when hospitalizations that lasted for more than 1 day were calculated.
Over the 11-year study, 58,195 (54.6%) patients received vaccinations. The most prevalent were DTPPHi (30.3%), influenza (19.2%), and pneumococcus (7.0%). Additional vaccines measured were only recorded, each, by less than 1% of patients.
Adjusted odds ratios (AORs) for flare-ups that resulted in hospitalization and vaccine administration during at-risk periods were 1.00 across all vaccines, 1.20 for pneumococcal, 0.98 for influenza, and 0.95 with DTPPHi vaccinations.
The researchers’ findings aligned with the previous studies that did not demonstrate significant increases in MS flare-ups after vaccine administration. Literature on this subject, as the authors note, has largely tested associations related to the influenza vaccine. Therefore, because risk was evaluated in relation to a plethora of vaccines, the current study adds valuable insight to this research.
The authors encourage further studies be conducted to expand on their results and investigate any effects of vaccine subtypes.
Reference
Grimaldi L, Papeix C, Hamon Y, et al. Vaccines and the risk of hospitalization for multiple sclerosis flare-ups. Jama Neurol. Published online September 5, 2023. doi:10.1001/jamaneurol.2023.2968
Real-World Data Show Sotorasib Effective for NSCLC With KRAS Mutation
May 18th 2024Data from real-world and clinical-trial settings on frontline monotherapy treatment with the KRAS inhibitor sotorasib both show similar progression-free survivals and a high likelihood that the treatment’s efficacy is not affected with dose reduction.
Read More
Health Equity and Access Weekly Roundup: May 18, 2024
May 18th 2024The US Senate hosted a panel addressing physician and health care shortages and efforts to increase minority representation in the medical field. An expert discussed initiatives to prevent senior homelessness. Advocates called for the repeal of the Comstock Act. Regulatory reforms are called for to improve rural cancer patients' access to pharmacies. Research reveals the impact of denials on patient access to immunology treatments.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More